<DOC>
	<DOCNO>NCT01679886</DOCNO>
	<brief_summary>The main objective study compare diagnostic performance 82Rubidium-PET associate pharmacologic stress ( Persantine ) 99mTc-Sestamibi-SPECT CZT camera associate stress test ( exercise , pharmacological , mixed ) detection myocardial ischemia population overweighed patient one hand , woman hand , population intermediate prevalence coronary artery disease ( ≥ 3 cardiovascular risk factor asymptomatic patient prevalence CAD ≥ 30 % use DIAMOND-FORRESTER score symptomatic patient ) .</brief_summary>
	<brief_title>Comparison Rubidium PET SPECT With CZT Crystals Detection Myocardial Ischemia Overweighed Patients Women</brief_title>
	<detailed_description>The main objective study compare diagnostic performance 82Rubidium-PET associate pharmacologic stress ( Persantine ) 99mTc-Sestamibi-SPECT CZT camera associate stress test ( exercise , pharmacological , mixed ) detection myocardial ischemia population overweighed patient one hand , woman hand , population intermediate prevalence coronary artery disease ( ≥ 3 cardiovascular risk factor asymptomatic patient prevalence CAD ≥ 30 % use DIAMOND-FORRESTER score symptomatic patient ) . Secondary objective . ( 1 ) Comparison size intensity myocardial ischemia quantify use sum difference score , leave ventricular function stress rest , measure 99mTc-Sestamibi-SPECT CZT camera 82Rubidium-PET . ( 2 ) Comparison value coronary fractional flow reserve measure invasively noninvasively 82Rubidium-PET patient stenosis ≥ 50 % coronary angiography . ( 3 ) Comparison effective dose cause radiation exposure 99mTc-Sestamibi-SPECT CZT camera 82Rubidium-PET . ( 4 ) Comparison cost two diagnostic strategy population patient . Inclusion criterion : Overweighed ( body mass index ≥ 25 ) woman address Department Nuclear Medicine diagnostic cardiac scintigraphy intermediate pre-test prevalence CAD ( ≥ 3 cardiovascular risk factor asymptomatic patient prevalence CAD ≥ 30 % use DIAMOND-FORRESTER score symptomatic patient ) . Non-inclusion criterion : Pregnant woman ; contraindication dipyridamole injection . Number patient : 310 patient Duration study . Duration study patient 16 month 28 month first patient . Total duration study 40 month , include 24-month inclusion time period . Primary endpoint : Patients classify positive case : - Myocardial ischemia define presence coronary stenosis ≥ 50 % coronary angiography functional impairment blood flow confirm invasive measurement coronary flow reserve ( fractional flow reserve , FFR &lt; 0.8 ) , , absence measurement FFR , critical coronary stenosis confirm validation committee coronary angiography . - In absence coronary angiography , presence cardiovascular event ( cardiovascular unknown cause death , admission acute coronary syndrome , unstable angina , myocardial ischemia coronary revascularization ) validate endpoint adjudication committee year follow inclusion patient study . Secondary endpoint : ( 1 ) Size intensity myocardial ischemia quantify use sum difference score , leave ventricular function stress rest , measure 99mTc-Sestamibi-SPECT CZT camera 82Rubidium-PET . ( 2 ) Values coronary fractional flow reserve measure invasively noninvasively 82Rubidium-PET patient stenosis ≥ 50 % coronary angiography . ( 3 ) Effective dose cause radiation exposure 99mTc-Sestamibi-SPECT CZT camera 82Rubidium-PET . ( 4 ) Costs two diagnostic strategy population patient .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>INCLUSION CRITERIA : Overweighed ( body mass index ≥ 25 ) woman address Department Nuclear Medicine diagnostic cardiac scintigraphy intermediate pretest prevalence CAD ( ≥ 3 cardiovascular risk factor asymptomatic patient prevalence CAD ≥ 30 % use DIAMONDFORRESTER score symptomatic patient ) . EXCLUSION CRITERIA : Pregnant woman ; Contraindication dipyridamole injection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Position emission tomography ;</keyword>
	<keyword>Rubidium ;</keyword>
	<keyword>Women ;</keyword>
	<keyword>Overweighted patient</keyword>
</DOC>